Drugs / SIMENEPAG ISOPROPYL
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00809848 | Feb → May 2009 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01291108 | Apr → Oct 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01001195 | Nov 2009 → Apr 2010 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIMENEPAG ISOPROPYL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105710 ↗ |
| Known as | AGN-210669 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00809848 ↗ |
| Action | Activate | “Prostanoid EP2 receptor agonist” CHEMBL2105710 ↗ |
| Modality | Small molecule | — CHEMBL2105710 ↗ |
| Route | Topical | “applied as 1 drop in both eyes every evening during Month 1 or Month 2” NCT01291108 ↗ |
| Target | PTGER2 | “Prostanoid EP2 receptor agonist” CHEMBL2105710 ↗ |